List of Excipients in Branded Drug OXANDROLONE

Generic Drugs Containing OXANDROLONE

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	oxandrolone	0245-0271	ANHYDROUS LACTOSE
Upsher-Smith Laboratories LLC	oxandrolone	0245-0271	HYPROMELLOSE
Upsher-Smith Laboratories LLC	oxandrolone	0245-0271	MAGNESIUM STEARATE
Upsher-Smith Laboratories LLC	oxandrolone	0245-0271	STARCH, CORN
Upsher-Smith Laboratories LLC	oxandrolone	0245-0272	ANHYDROUS LACTOSE

What are the Most Frequently-Used Excipients in OXANDROLONE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	HYPROMELLOSE
2	LACTOSE MONOHYDRATE
4	MAGNESIUM STEARATE
4	STARCH, CORN

Oxandrolone Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Oxandrolone is an old, orally active anabolic androgenic steroid with limited active-ingredient patent protection and a primarily generic commercial market. The strongest opportunities are differentiated oral formulations, hospital-use packaging, pediatric and geriatric dosage forms, and products that improve dose uniformity, swallowability, and supply reliability. Conventional immediate-release tablets remain the lowest-risk entry route, while liquids, orally disintegrating tablets, and multiparticulate systems offer higher commercial differentiation but greater regulatory and stability requirements.

What is oxandrolone and how is it regulated?

Oxandrolone is a synthetic testosterone derivative marketed historically in the United States as Oxandrin. It is administered orally and has been used as an adjunct to promote weight gain after surgery, chronic infection, severe trauma, or prolonged corticosteroid exposure. Its clinical use is constrained by anabolic-steroid safety warnings, hepatic risks, lipid changes, virilization, and controlled-substance requirements.

Regulatory or product attribute	Oxandrolone position
Active ingredient	Oxandrolone
Common strengths	2.5 mg and 10 mg tablets
Dosage form	Immediate-release oral tablet
Historical U.S. brand	Oxandrin
U.S. regulatory pathway	FDA-approved NDA and generic ANDA products
Controlled-substance status	Schedule III anabolic steroid under U.S. federal law
Primary commercial market	Generic prescription tablets
Biologic or biosimilar exposure	None
Main formulation issue	Low-strength dose uniformity and oral administration
Main regulatory concern	Anabolic-steroid safety labeling and controlled distribution

The FDA has listed Oxandrin as discontinued for commercial reasons rather than withdrawal for safety or effectiveness. That status does not eliminate FDA approval of generic oxandrolone products. The Orange Book and FDA Drugs@FDA databases remain the primary sources for current reference-product and generic status [1, 2].

What excipients are used in oxandrolone tablets?

Oxandrolone tablets commonly use standard direct-compression or wet-granulation excipients. The exact composition depends on the manufacturer and strength.

Typical excipient classes include:

Excipient function	Candidate materials	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Controls tablet mass and improves manufacturability
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces compression and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Coating system	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves handling, appearance, and swallowability
Sweetener or flavor	Sucralose, mannitol, flavor systems	Relevant to liquid, ODT, and pediatric products

Because oxandrolone is administered at low milligram strengths, the excipient system has a direct effect on content uniformity. A 2.5 mg tablet contains a relatively small quantity of active ingredient, making segregation, over-lubrication, and poor powder flow important development risks.

Current commercial labels should be reviewed product by product because inactive ingredients are not necessarily identical across generic manufacturers. DailyMed provides manufacturer-specific labeling and inactive-ingredient information [3].

How should an oxandrolone excipient strategy be designed?

The preferred excipient strategy depends on the commercial objective.

Immediate-release generic tablets

For a conventional ANDA, the most defensible formulation is a simple immediate-release tablet using well-characterized excipients with established FDA Inactive Ingredient Database precedent.

A practical design would use:

• Microcrystalline cellulose or lactose as the primary diluent
• Crospovidone or croscarmellose sodium as the disintegrant
• Povidone or pregelatinized starch as the binder
• Magnesium stearate at a controlled concentration
• Colloidal silicon dioxide for flow improvement
• Film coating only where needed for swallowability, identification, or moisture protection

The development target should be rapid dissolution, strong content uniformity, low friability, and stable assay under accelerated and long-term conditions. Excessive lubricant can slow dissolution, particularly in a low-dose tablet with a high excipient-to-drug ratio.

Lactose-free formulations

A lactose-free tablet can target patients with lactose intolerance, institutional formularies that restrict lactose, or manufacturers seeking a broader excipient profile. Microcrystalline cellulose, mannitol, and dibasic calcium phosphate can replace lactose, although each creates different compression, density, and dissolution characteristics.

The commercial value is moderate. Lactose-free positioning alone is unlikely to support a premium unless it is combined with improved swallowing, unit-dose packaging, or a shortage-resilient supply proposition.

Moisture-protective formulations

Oxandrolone tablets may benefit from packaging and coating designed to limit moisture exposure. Relevant options include:

• High-barrier PVC/PVdC or aluminum blister packaging
• Desiccant-containing bottles
• Film coatings with low water permeability
• Tighter control of hygroscopic excipients
• Lower-moisture granulation processes

Packaging is often a more cost-effective stability intervention than a complex excipient system. A manufacturer can create commercial value through longer in-use stability, institutional packaging, and reduced tablet degradation without introducing a new delivery technology.

What formulation patents could protect oxandrolone products?

The oxandrolone active moiety is old, and basic tablet compositions are unlikely to provide meaningful long-term exclusivity. Commercial protection would more likely arise from a specific formulation or delivery platform.

Potentially protectable areas include:

1. A rapidly disintegrating tablet with defined dissolution performance.
2. An orally disintegrating tablet with controlled particle size and taste masking.
3. A stable aqueous or nonaqueous oral suspension.
4. A multiparticulate formulation that improves dose uniformity.
5. A solid dispersion or lipid-based system that increases apparent solubility.
6. A unit-dose formulation designed for hospital or pediatric administration.
7. A formulation that reduces exposure to a defined degradation pathway.
8. A combination of particle engineering, excipient ratio, and dissolution profile.

The patentability threshold is high. A formulation claim would need a defensible combination of composition and performance limitations. Routine substitution of lactose with microcrystalline cellulose, or one disintegrant for another, normally provides weak patent positioning unless supported by unexpected stability, bioavailability, or manufacturing results.

How many patents cover oxandrolone?

No meaningful active-ingredient patent barrier is expected for oxandrolone in the United States. The molecule was developed decades ago, and the historic Oxandrin product does not represent a modern composition-of-matter exclusivity position.

Patent risk should be separated into four categories:

Patent category	Expected risk
Composition of matter	Low
Basic immediate-release tablet	Low
Novel delivery system	Moderate, depending on claims
Method of treatment	Potentially relevant but commercially narrow

The relevant diligence question is not whether oxandrolone has an old patent estate. It is whether a proposed product would practice a later formulation, manufacturing, or method-of-use patent held by another party. A current freedom-to-operate review should search U.S. patents, pending applications, Orange Book listings, and litigation records for the exact dosage form and manufacturing process.

When does oxandrolone lose exclusivity?

Oxandrolone’s original small-molecule exclusivity has expired. Generic competition is therefore permitted through the ANDA pathway, subject to product-specific FDA requirements.

The key commercial distinction is between:

• Expired active-ingredient exclusivity
• Current approval of individual generic products
• Any later patent covering a formulation or method of use
• Controlled-substance manufacturing and distribution compliance

The absence of active compound exclusivity does not guarantee immediate market entry. Generic manufacturers still need an approved ANDA, an acceptable abbreviated clinical and bioequivalence package, current Good Manufacturing Practice compliance, and supply capacity.

What is the Orange Book status of oxandrolone?

The Orange Book identifies FDA-approved drug products and applicable patent or exclusivity information. Oxandrolone products should be evaluated by reference NDA, dosage strength, and active ANDA status rather than by brand history alone [1].

Oxandrolone has no biosimilar pathway because it is a chemically synthesized small molecule. A follow-on product would generally use an ANDA if it meets sameness, bioequivalence, and labeling requirements. A 505(b)(2) application could be relevant for a new dosage form, such as a liquid or ODT, where the applicant relies partly on existing oxandrolone safety and efficacy information but introduces a clinically or technically distinct product.

Which oxandrolone formulations offer the strongest commercial opportunity?

Oral solution or suspension

A liquid product could address patients who cannot swallow tablets, including pediatric, geriatric, oncology, trauma, and intensive-care populations. The principal formulation challenges are:

• Low aqueous solubility
• Dose uniformity during storage and dispensing
• Sedimentation or crystal growth in suspensions
• Palatability
• Preservative compatibility
• Container adsorption and extractables
• Controlled-substance measurement and diversion control

A suspension is more likely than a true aqueous solution unless solubility-enhancing technology is used. Candidate approaches include micronized drug, wetting agents, suspending polymers, cosolvents, and taste-masking systems. High concentrations of surfactant or cosolvent may create tolerability and regulatory complications.

Orally disintegrating tablet

An ODT could improve administration for patients with dysphagia and reduce the need for water. Suitable excipients include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and compactible co-processed excipients.

The main development risks are:

• Bitter or metallic steroid taste
• Tablet friability
• Sensitivity to humidity
• Inadequate mechanical strength
• Inconsistent disintegration after packaging
• Difficulty achieving acceptable mouthfeel at the 10 mg strength

Taste masking should be designed around particle coating, ion-complexing, polymer barriers, or flavor systems. A simple sweetener addition is unlikely to overcome the taste of a potent steroid.

Oral film

A thin oral film could offer portability and controlled administration, but the commercial case is less certain. The product would need reliable drug loading, uniformity across the film, adequate strip strength, and acceptable taste. Oxandrolone’s controlled-substance status would also create packaging and diversion-control requirements.

Multiparticulate capsules

Multiparticulates can improve dose distribution and support sprinkle administration. They also allow separation of taste masking, disintegration, and release-control functions. This approach has higher manufacturing complexity than a tablet but could support a differentiated pediatric or dysphagia product.

What generic entry risks exist for oxandrolone?

Generic entry risk is high for standard tablets and moderate for differentiated dosage forms.

Product concept	Generic competition	Development burden	Commercial differentiation
2.5 mg immediate-release tablet	High	Low to moderate	Low
10 mg immediate-release tablet	High	Low to moderate	Low
Lactose-free tablet	High	Moderate	Low to moderate
Film-coated swallowable tablet	High	Moderate	Moderate
ODT	Moderate	Moderate to high	Moderate to high
Oral suspension	Lower	High	High
Oral solution	Lower	High	High
Multiparticulate sprinkle product	Lower	High	High

The largest risk for a conventional tablet is price erosion. Oxandrolone has an old active ingredient, multiple potential generic suppliers, and limited ability to command a premium without a supply, formulation, or distribution advantage.

Are there Paragraph IV challenges or oxandrolone patent lawsuits?

Paragraph IV litigation is likely to be limited because the original active-ingredient patent estate has expired and the product is primarily generic. A Paragraph IV certification could still arise against a later-listed formulation or method-of-use patent, but the commercial significance would depend on the scope and remaining term of that patent.

Public FDA sources should be reviewed for current patent listings, while PACER and court databases should be reviewed for active cases, settlements, or launch restrictions. No material current oxandrolone litigation or settlement should be assumed solely from the historical Oxandrin brand record.

What manufacturing and excipient barriers affect oxandrolone?

Manufacturing barriers are manageable but relevant:

• Low-dose content uniformity
• Segregation during blending
• Control of particle size and bulk density
• Lubrication effects on dissolution
• Moisture sensitivity
• Controlled-substance inventory controls
• Dedicated analytical methods for assay and related substances
• Cleaning validation for steroid residues
• Reliable sourcing of pharmaceutical-grade excipients

A manufacturer can create an operational advantage through continuous blending, high-shear granulation, engineered excipients, or improved containment. These measures are more likely to protect margin and supply reliability than to create standalone patent value.

How does oxandrolone compare with competing anabolic therapies?

Oxandrolone competes with other anabolic agents and with non-anabolic strategies for weight gain and muscle preservation.

Therapy category	Oxandrolone advantage	Oxandrolone disadvantage
Other anabolic steroids	Oral dosing and established tablet manufacturing	Hepatic and androgenic risks
Testosterone products	Oral tablet convenience	Less suitable for testosterone-replacement positioning
Megestrol acetate	Different appetite and weight-gain profile	Oxandrolone has anabolic rather than primarily appetite-stimulant positioning
Nutritional formulations	Drug-like dosing and targeted use	Greater regulatory and safety burden
Injectable anabolic products	Avoids injection	Oral hepatic exposure and adherence issues

The commercial opportunity is strongest where oral administration, low dose, and a controlled indication matter more than broad population prescribing.

What licensing opportunities exist for oxandrolone?

Licensing value is more likely to reside in technology than in the oxandrolone molecule. Attractive assets include:

• Taste-masking platforms
• Pediatric liquid systems
• Low-dose content-uniformity technology
• Moisture-protective packaging
• Multiparticulate sprinkle technology
• Contract manufacturing capacity for controlled oral solids
• Regional rights in markets where oxandrolone supply is limited

A license for an old immediate-release tablet would have limited strategic value unless it includes an approved ANDA, established manufacturing, or dependable supply contracts. A differentiated dosage form with a defensible patent family could command a stronger valuation, particularly if it has FDA clinical or bioequivalence support.

What FDA pathway is most appropriate for a new oxandrolone product?

An ANDA is generally appropriate for a conventional tablet that matches the reference product in active ingredient, dosage form, strength, route, and performance.

A 505(b)(2) strategy may be appropriate for:

• A liquid formulation
• An ODT with materially different administration
• A new release profile
• A novel administration route
• A product requiring clinical bridging beyond standard ANDA bioequivalence

FDA approval would still require controlled-substance compliance, adequate labeling, chemistry and manufacturing controls, stability data, and appropriate bioequivalence or clinical evidence. Excipient changes must be supported by safety precedent, product-specific justification, and finished-product performance data [2, 4].

Key Takeaways

• Oxandrolone has an expired active-ingredient exclusivity position and a mainly generic market.
• Standard 2.5 mg and 10 mg tablets offer the lowest regulatory risk but limited margin potential.
• Excipient selection is central to low-dose content uniformity, tablet strength, dissolution, and stability.
• The most credible differentiated opportunities are oral suspension, ODT, multiparticulate, and hospital-friendly unit-dose products.
• Lactose-free and moisture-protective tablets may improve market access but are weak standalone patent strategies.
• A 505(b)(2) pathway may be relevant for a clinically or technically differentiated dosage form.
• The principal commercial barriers are price erosion, controlled-substance compliance, manufacturing scale, and limited prescriber demand.
• Patent value is more likely to arise from formulation, manufacturing, or delivery technology than from oxandrolone itself.
• No biosimilar risk applies because oxandrolone is a small molecule.
• A current freedom-to-operate review should focus on later formulation and method-of-use patents, not the original compound.

FAQs About Oxandrolone Excipient and Commercial Strategy

Can oxandrolone be formulated as a pediatric liquid?

Yes, but the formulation must address solubility, taste, dose uniformity, preservative compatibility, and controlled-substance handling. A suspension is generally more practical than a high-concentration aqueous solution.

Which excipient is best for an oxandrolone ODT?

Mannitol is a strong starting diluent because it supports mouthfeel and rapid dispersion. Crospovidone or low-substituted hydroxypropyl cellulose can support disintegration, but the final system must be optimized around taste masking and humidity sensitivity.

Is a lactose-free oxandrolone tablet commercially valuable?

It can serve institutional and patient segments that avoid lactose, but lactose-free status alone is unlikely to support substantial price differentiation in a generic market.

Could a new oxandrolone formulation receive U.S. market exclusivity?

A novel formulation approved under a qualifying regulatory pathway may receive product-specific exclusivity, but the duration and scope would depend on the application type, clinical requirements, and FDA determination.

What is the largest commercial risk for a new oxandrolone product?

For conventional tablets, the largest risk is generic price competition. For liquids and ODTs, the larger risks are development cost, limited market size, taste and stability failure, and the need to establish clinical or bioequivalence support.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
3. National Library of Medicine. (n.d.). DailyMed: Oxandrolone drug labels. https://dailymed.nlm.nih.gov/dailymed/
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm